223 related articles for article (PubMed ID: 36068158)
1. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
Al-Mansour M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
[TBL] [Abstract][Full Text] [Related]
2. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
3. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
5. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK; Gerber D; Zhang C; Cohen JB
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
[TBL] [Abstract][Full Text] [Related]
7. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
9. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Munoz JL; Wang Y; Jain P; Wang M
Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
11. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
14. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
15. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
[TBL] [Abstract][Full Text] [Related]
16. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
Arun Kumar S; Gao J; Patel SA
Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
[TBL] [Abstract][Full Text] [Related]
17. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
19. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
